Bausch & Lomb
This article was originally published in The Gray Sheet
Executive Summary
Firm commences hostile takeover bid for tinted contact lens maker Wesley Jessen April 3 via $34-per-share tender offer (1"The Gray Sheet" April 3, In Brief). Separately, B&L filed a lawsuit in the Court of Chancery of Delaware against Wesley Jessen and Ocular Sciences seeking "injunctive relief" against the Wesley Jessen/Ocular Sciences merger agreement of March 20, redemption of Wesley Jessen's "poison pill" anti-takeover provisions and "a declaration that any breakup fee Ocular receives it holds as a constructive trustee," B&L states
You may also be interested in...
Ocular Sciences v. Bausch & Lomb
Lawsuit filed in California state court seeks injunctive relief, compensatory and punitive damages from Bausch & Lomb for tortious interference with the March 20 definitive merger agreement between Ocular and Wesley Jessen. The suit is the latest salvo in a tug of war for Wesley Jessen. B&L launched a hostile $34-per-share takeover bid for Wesley Jessen April 3 and filed a lawsuit against Wesley Jessen and Ocular seeking injunctive relief against the merger in the Court of Chancery of Delaware (1"The Gray Sheet" April 10, In Brief)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.